Linical posts deeper nine-month loss but maintains full-year forecast and dividend plan

Linical Co., Ltd. ( (JP:2183) ) has issued an announcement.

Linical Co., Ltd. reported consolidated net sales of ¥6.84 billion for the nine months ended December 31, 2025, down 14% year on year, and posted an operating loss of ¥1.28 billion and a net loss attributable to owners of the parent of ¥1.55 billion, deepening losses from the previous year. Total assets fell to ¥13.99 billion and the shareholders’ equity ratio declined to 40.5%, but the company kept its full-year forecast unchanged, projecting a continued net loss while still planning an annual dividend of ¥16 per share for the year ending March 31, 2026.

The deterioration in earnings has also weighed on Linical’s financial position, with net assets shrinking to ¥5.67 billion and net asset per share dropping to ¥251.02 as of December 31, 2025. Despite the worsening profitability and lower equity ratio, management is not revising its guidance, signaling expectations that current headwinds are manageable while maintaining shareholder returns through stable dividend payments.

The most recent analyst rating on (JP:2183) stock is a Sell with a Yen286.00 price target. To see the full list of analyst forecasts on Linical Co., Ltd. stock, see the JP:2183 Stock Forecast page.

More about Linical Co., Ltd.

Linical Co., Ltd. is a Japan-based contract research organization listed on the Tokyo Stock Exchange, providing clinical development and related services to pharmaceutical and biotech companies. The firm focuses on supporting drug development through outsourced clinical trial operations across global markets, positioning itself within the broader healthcare and life sciences services industry.

Average Trading Volume: 43,261

Technical Sentiment Signal: Sell

Current Market Cap: Yen7.16B

See more insights into 2183 stock on TipRanks’ Stock Analysis page.